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Background: Health care in the United States is in the midst of a near perfect storm: strong cost pressures,
dramatic redesign efforts like patient-centered medical homes and accountable care organizations, and a broad
series of payment and eligibility reforms. To date, alternative models of care intended to reduce costs and improve
outcomes have shown mixed effects in the U.S., in part due to the difficulty of performing rigorous evaluation
studies that control for the broader transformation while avoiding other biases, such as organizational or clinic
effect on individual patient outcomes. Our objective is to test whether clinics assigned to achieve high value
elements (HVEs) of practice redesign are more likely than controls to achieve improvements in patient health and
satisfaction with care and reduction in costs.
Methods/Design: To prepare, we interview stakeholders, align with health reform, and propose a pilot.
Participants are primary care clinics engaged in reform. Study protocol requires that both arms receive monthly
practice facilitation, IT-based milestone reporting, and small financial incentives based on self-determined quality
improvement (QI) goals; intervention receives additional prompting to choose HVEs. Design is a cluster randomized
controlled trial over 1 year with pre- and post-washout periods. Outcomes are unplanned utilization and costs, patient
experience of care, quality, and team performance. Analysis is a multivariate difference-in-difference with adjustments
for patient risk, intraclinic correlation, and other confounders.
Discussion: The TOPMED study is a cluster randomized controlled trial focused on learning how primary care practices
can transform within health reform guidelines to achieve outcomes related to the Triple Aim.
Trial registration: ClinicalTrials.gov registration: NCT02106221.Introduction
United States health care costs per capita are more than
50% larger than other developed countries, yet our
health outcomes lag in many respects [1]. To combat
this disparity, the U.S. is engaged in a number of health
reform efforts. For instance, billions are being invested* Correspondence: dorrd@ohsu.edu
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virtually integrate health systems, align incentives, and
optimize care for populations—and patient-centered
medical homes (PCMHs)—intended to change the in-
centives and impact of primary care settings to better
engage patients, improve quality, and improve care coord-
ination [2]. However, the evidence about how to reform
care in a complex and fragmented system is unclear [3,4]
and the outcomes of previous efforts are mixed [5-8]. Al-
though trial design has grown increasingly sophisticatedis is an Open Access article distributed under the terms of the Creative
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midst of large health reform efforts is still challenging.
Analyses have shown that intervention definitions, con-
temporaneous trends, sample size estimates, and unit of
analysis all confuse results [4]. In this paper, we describe
the protocol of a complex cluster randomized controlled
trial named Transforming Outcomes for Patients through
Medical Home Evaluation and reDesign or TOPMED.
TOPMED is intended to test whether primary care
clinics in Oregon engaged in both PCMH- and ACO-
like redesign efforts can improve outcomes. In Oregon,
coordinated care organizations are ACO-like models
that bundle care for Medicaid patients, creating or
adapting regional entities whose goals are to reduce cost
of care while meeting benchmarks in quality and patient
experience of care. Their primary approach involves care
coordination, increased population management systems
with stratification, and combining previously disparate
systems like mental health, housing, and health systems
in novel ways [9]. Similarly, for PCMH, Oregon chose a
state recognition process (called the patient-centered
primary care home) and payment reform through efforts
like the Comprehensive Primary Care (CPC) initiative,
funded through the Centers for Medicare and Medicaid
Services (CMS), and primary care clinics are receiving a
combination of proactive care management payments
and shared savings to increase population management,
care coordination, quality improvement, and engaging
patients and families.
Previous evidence of the effectiveness of these models
is mixed. Studies at Group Health, Geisinger, and Inter-
mountain Healthcare demonstrated success [5,6,10], but
several others, including the national demonstration
project (NDP), a cluster randomized trial of 36 primary
care clinics, improved quality metrics but failed to affect
the key outcomes of cost, utilization, and patient experi-
ence [7]. Since the definitions of PCMHs are complex,
we and others have identified key concepts—what we
call ‘high-value elements’—that may help lead to success.
In the Care Management Plus (CMP) trial at Intermoun-
tain, which studied the use of care managers embedded
in seven primary care clinics compared to a set of matched
control clinics, success factors included an integrated care
manager, an IT-based population management system,
training in complex illness care, motivational interviewing,
self-management and goal setting, and how to address is-
sues for older adults and patients identified at higher risk.
In all, 1,440 patients with complex illness needs were re-
ferred during the 2-year study period. For similar patients
with multiple chronic illnesses, hospitalizations were re-
duced by 24%–40%, patient satisfaction was higher, and
patient health status was improved for those referred to
care management compared to controls. Similarly, Brown
et al. identified seven characteristics that defined theeffective Medicare chronic care demonstration sites: 1)
care coordinators with face-to-face contact with patients;
2) strong relationships with physicians; 3) patient educa-
tion; 4) managing care transitions; 5) acting as a communi-
cations hub; 6) medication management; and 7) addressing
psychosocial issues [3].
A number of these concepts—care coordination, care
management, population management, use of IT, focus-
ing on complex patients—are used in PCMH and ACO-
like models, but most of the elements do not directly
relate to known drivers of cost reduction [11]. Thus, in
pursuing health reform, clinics have many different paths
to choose to achieve transformation and potentially im-
pact these outcomes. Assistance in transformation such as
learning collaboratives and practice facilitation may help
but does not appear to be sufficient to consistently achieve
desired outcomes [12]. We wanted to understand if we
could use practice facilitation coupled with IT and incen-
tives to drive clinics towards more effective components.
However, trial design in health reform is notoriously com-
plex, with previous reviews demonstrating multiple biases
and confounders that threaten study validity and success
[12]. In addition, pragmatic trial design requires a protocol
that can work in the real world; that is, where clinical
teams need flexibility, to maintain autonomy and decision-
making as much as possible, and are not burdened with
additional study requests.
In our trial design process for TOPMED, we attempted
to understand how one could overcome the weaknesses
and mixed outcomes of previous trials. Building upon re-
cent efforts, TOPMED integrates lessons from model im-
plementation and trial design into health reform efforts
while revising study design to account for biases. Thus, we
create a trial aligned with these efforts to understand if a
more targeted approach to primary care transformation is
more effective than the general approach. We use a cluster
randomized control trial design because our intervention
involves quality improvement efforts at the organizational
level of practice sites.
Objectives
The objective of this study is to understand whether fo-
cused versus general quality improvement efforts in a
pragmatic cluster randomized trial can facilitate im-
provement in patients’ health and satisfaction with care
while reducing costs. The trial outcomes and hypotheses
are both at the cluster and patient level.
The study has two major research questions:
1) Would a study aligned with major reform efforts with
focused practice facilitation, targeted incentives, and
IT-based reporting enhance quality improvement
capability and likely achievement of selected health
reform goals within the clinics?
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elements’ from the many choices in health reform
can improve outcomes more than general quality
improvement?
Methods/Design
The proposed trial design is a cluster randomized con-
trolled trial with a high-value element (intervention) and
a general quality improvement arm (control), where
randomization is at the clinic level and matching is used
to minimize baseline clinic differences between arms.
Preparation
We took several complementary approaches to explore
different trial design options in the complex health reform
environment for the TOPMED trial. First, we matched the
trial design to the PRECIS pragmatic trial framework and
reviewed trial literature. Second, we aligned trial imple-
mentation and components with major health reform ele-
ments. Third, a series of stakeholder interviews and focus
groups were held to understand the values, understand-
ings, perceptions, and intentions in regard to the health
reform efforts and the potential for the trial design to be
nested within these efforts. Finally, a pilot was completed
to test various elements prior to the study start.
Changes to the trial design from this initial set of tasks
are outlined in Table 1. The PRECIS framework recom-
mends health professional and patient autonomy over trial
protocol inflexibility and prescription, and the trial was
broadened to allow flexibility in quality improvement (QI)
decision-making, meeting practices where they are in terms
of capacity for change. The alignment with payers and
other stakeholders demonstrated that certain principles
could be agreed upon, but flexibility was needed and sim-
plification was required for specific improvement. Patients
focused on access and information gaps; subsequently, we
included access-related high-value elements, and all trial el-
ements were translated to patient-specific language.Table 1 Preparation steps for trial design
Aspect Results
PRECIS (pragmatic trial) review Initial high-value elements we
too focused and prescriptive
Alignment with health reform via
multistakeholder panel (N = 12)
Incentives too complex; lack o
with other health reform effor
and clinic culture will drive res
Chronic illness patient focus group (N = 9) Access to the clinic and the sp
need to be improved; informa
about what is newly available
(like care coordination) was co
Insurer focus group (N = 22) Each insurer had their own in
separate take on the current i
Pilot clinic interviews (N = 6) Expectations of the clinic too
and time-consumingPilot study
A 6-month pilot at a single practice site was performed to
test the various interventions and refine efforts. At the pilot
site, preparation and protocol elements were tested in a
series of six monthly practice facilitation visits. At each
visit, an aspect of the trial design was tested for feasibility,
clarity, and usability. The pilot team was interviewed for
the results, and results demonstrated that the expectations
were too vague and time-consuming. A memorandum of
agreement was drawn up with specific expectations for
both the research team and the clinic team. These included
a role-based specification by clinic of time expected, use of
data, and communication required to participate, as well as
clear roles for researchers. The protocol visits by practice
facilitators were honed to focus on key drivers of quality
improvement and transformation: leadership, team-based
approach, QI infrastructure, setting new improvement tar-
gets, and follow-up on previous improvement targets. Re-
ports were assessed for comprehension and revised, and
use of the IT system for study participation was reduced,
allowing clinics to use their own protocols and tools when
they matched the function of the IT system.
Participants
Participants are eight primary care clinics (clusters) that
are deeply engaged in health reform, are willing to use a
population management registry tool, are willing to re-
ceive practice facilitation and improve their performance,
and use an electronic health record (EHR) system at base-
line. A goal was set to recruit a diverse set of participant
clinics by ownership, location (rural versus urban), and
size (from 3 to 20 providers). Patients, providers, and staff
of these clinics are consented separately when their spe-
cific opinions or viewpoints are elicited (via surveys or in-
terviews), with no penalty for non-participation. Data is
collected at the clinics during facilitation sessions, from
the EHR through automated extraction and from patients,
providers, and staff via paper and online surveys.Changes made





Generated alignment document; revised intervention
metrics and approach to better align with initiatives;




Look carefully for patient experience measures that
examine access and information gathering; expect
different experiences from patients than reported
by clinics; improve education
itiative or had a
nitiative set
Aligned principles were agreed to by payers;
encourage payer alignment
vague Generated a memorandum of understanding
that clinics revised and implemented
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The final trial design, shown in Figure 1, is a two-arm,
cluster randomized controlled trial with clustering at the
clinic level and stratification by size, location, and popu-
lation. We considered a factorial design and a third arm
with extant patient-centered medical homes but no spe-
cific interventions (usual care), but contamination pre-
vented a factorial design and the third arm required
access to unavailable clinic data.
These components consist of three aspects aimed at
the clinic level: 1) incentives with audit and feedback
based on overall and incremental goal performance; 2)
an HIT system called the Integrated Care Coordination
Information System (ICCIS) that measured care on indi-
vidual patients as well as progress towards clinic goals;
and 3) tailored practice facilitation. The sole difference
between the intervention and control arm is that the
control arm is given free rein to address any health re-
form goal and the intervention arm is encouraged—both
through practice facilitation and incentives—to focus
their transformation efforts on achieving as many high-
value elements as possible. A summary is shown in
Table 2 below. Across five topic areas for high-value ele-
ments, 12 subtopics were developed into 26 specific mea-
sures that allow flexibility and increase achievement.
Components such as identification of at-risk population
and care management are measured by provision of care
plans, offering advanced directives, and outreach to high-
risk populations. Patient engagement and proactive goal
setting involve self-management support and reminders.
Integrating information focuses on clinical information ex-
change and follow-up post-utilization, while population
management focuses on the use of population manage-
ment tools to proactively manage metrics and certain out-
reach components. Finally, access was added based on
patient-identified need; after-hours access and availability
of providers are the identified elements from the focusFigure 1 TOPMED final trial design (see accompanying file).group. Alignment with health reform metrics is moderate
to strong. Moderate alignment was defined as some over-
lap with the general area of health reform, but the
metric did not exist in the reform model. For instance,
risk stratified care management concepts were not mea-
sures in the reviewed initiatives but rather general goals.
Strong alignment means that the precise measure was or
is in place elsewhere, but the benchmark was more ad-
vanced or specific. For instance, follow-up on utilization is
a specific CPC metric, but the study benchmark of 70% is
more aggressive.
Trial implementation and monitoring
Clinics are eligible for the same amount of incentives.
Practice facilitation is offered monthly to both interven-
tion and control since recent summary literature sug-
gests that practice facilitation both makes it possible to
transform and directly affects outcomes of trials. At each
visit, clinics are free to select from a wide variety of
choices based on their current needs; while the control
arm has 35, the intervention arm has 12 options. Previ-
ous goals are assessed by the practice facilitator and new
ones set. The IT system is available at all times, with
functions of risk stratification (built in scores), care
management tracking, and self-assessment of all PCMH
elements available for clinical team review. The incentive
reports are built into the IT system, with the interven-
tion and control receiving a general score based on set-
ting and meeting QI goals, and intervention receiving a
multiplier based on the number of high-value elements
met. The multiplier, whose maximum was 2, set 30% of
the potential incentive aside for HVE achievement. Once
the clinics meet a HVE threshold of 2/3 of the elements
achieved, they earn up to a 10% bonus for achieving
additional elements. Additional file 1 shows the pro-
posed IT reports for intervention and control.
The process to generate the scores was tested during the
pilot study. In general, effort at QI is rewarded on a 0%–
100% scale; factors included in the score generation are
organization around QI, leadership involvement, team
function, and setting and follow-up on goals. From the
practice facilitator’s notes each month, a team of three in-
vestigators review each element and decide on a total
score. This score is fed back at each visit, with a summary
report of overall performance versus other clinics each
quarter. The pilot clinic demonstrated a strong response
to the reward of effort and the competition engendered by
a ‘grading’ approach; they did require significant explan-
ation of the scoring rubric and requested the opportunity
to offer feedback to get a score adjusted.
Outcomes and measures
There are three sets of measures planned for the trial.
First, primary and secondary outcomes are aligned with
Table 2 Intervention ‘high-value’ elements
Element Description Specific example metric* Alignment
with reform
Identification of at-risk populations
and care management
Care plan utilization Tier 3—PCMH provides care plans
to >50% of high-risk patients.
Moderate
Advance directive utilization Tier 3—The PCMH offers advance directives
to at least 50% of patients over 65.
Based on need Care management outreach Tier 2—PCMH’s care coordination outreach
reaches 50% of high-risk patients.
Patient engagement and
proactive goal setting
Education and self-management resources Tier 2—More than 10% of all unique patients
are provided patient-specific education
resources and self-management services.
Strong
Reminders Tier 3—PCMH sends appropriate reminders
to at least 20% of all eligible patients.
Integrated information and
procedures across settings
Clinical information exchange Tier 1—PCMH exchanges structured clinical
information and tracks critical
elements (e.g., hospitalizations).
Strong
Utilization monitoring and follow-up Tier 3—PCMH follows up on patient
hospitalizations and ED visits 70% of
the time (when they have the information).
Population management tools Performance data utilization Tier 1—The PCMH uses performance data
to identify opportunities for improvement
and acts to improve clinical quality, efficiency,
and patient experience.
Strong
Receive and respond to electronic requests Tier 3—The PCMH provides a response
to online or electronic queries
within two business days.
Improved access After-hours access Tier 1—PCMH offers access to in-person
care at least 12 h weekly outside
traditional business hours.
Strong
Tracking 3rd next available appointments
*Nine metrics are solely applicable to primary care, and eight include primary care and other aspects of the health care system.
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and population health, with specific expected decreases
planned as clinically meaningful and to set sample size.
Primary outcomes are reduction in total cost of care for
patients, with a focus on hospitalization rate and ED visit
rate of patients as indicator measures. A reduction in
utilization up to 20% per year has been seen in some re-
lated studies, but a conservative estimate of 10% relative
reduction in utilization is planned for this study. Measure-
ment of this outcome will be completed through a state-
based All Payer All Claims database, which allows for
attribution of patients to a clinic based on visits to primary
care, and contains all claims for that individual across in-
surance types. This outcome and its specific measurement
are strongly related to the health reform goals, using the
same metrics for success. For experience of care, the Clin-
ician and Group Consumer Assessment of Healthcare
Providers and Systems (CG-CAHPS) surveys at the pa-
tient level will be used, with an expectation of a 10% im-
provement in experience of care metrics closely related to
the high-value elements. There are 11 composite scores,
and 4 are determined to be closely aligned to the study
aims: 1) providers support you in taking care of your own
health; 2) providers pay attention to your mental oremotional health; 3) follow-up on results; and 4) access to
care. A secondary outcome is a composite quality score at
the clinic level based on standard chronic illness health re-
form measures used for the clinics. A 10% increase is ex-
pected in the control clinics, since previous work has
shown that clinics often focus on common quality mea-
sures first. Table 3 outlines primary, secondary, and
monitoring outcomes, along with their respective met-
rics and data sources.
Other secondary outcomes include measurements at the
cluster and patient level based on stakeholder suggestion.
For clinics, culture, microsystem team performance, co-
ordination and collaboration, and adaptive reserve were
felt by stakeholders and seen in the literature to be crucial
to measure before and after the trial; thus, we will use the
clinician staff questionnaire (CSQ), the Team Develop-
ment Measure (TDM), the Collaborative Practice Assess-
ment Tool (CPAT), and a novel collaboration tool for
external collaboration between clinical teams. Qualitative
interviews with patients and with clinics will be performed
to understand the impact of study more broadly. Monitor-
ing goals were discussed above but required monthly as-
sessments of clinic engagement with QI goal setting and
follow-up as well as the high-value elements will provide
Table 3 Primary, secondary, and monitoring outcomes
Metrics Measurement source Alignment with
health reform
Primary outcome goals





ED visit rate per patient per month




Improve quality of care by 10% Composite of nine composite measures EHR-based electronic clinical
quality measures; clinic level
Strong: same measures used
Improve teamness, collaboration,
and patient-centered care
Composites of various tools CSQ, TDM, CPAT, and novel
collaboration tool; clinic level
Indirect
Monitoring goals
Clusters engage in quality improvement Monthly ‘score’ based on




HVE passed monthly Monthly count of HVEs passed HVEs derived from PCMH;
clinic level
Strong
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will be recorded and used to calculate protocol adherence.
Sample size
The sample size was based on eight hypothetical clinics
with an average of 10,000 patients each. The intracluster
correlation was estimated at .02, and the necessary sample
size to detect a change of 10% in cost and utilization over
the year was <6,000 patients with average costs of $730
per month (average Medicare spend for our region) and
average hospitalization rates of 14% at a power of > .80.
Besides the monitoring metrics, above, no interim analyses
or stopping guidelines were planned due to the low risk of
the study.
Randomization
For randomization, with a small number of clusters (8),
the study requires significant work to assure baseline
similarities, where possible, and analytic techniques to
adjust for site-specific differences. To that end, we used
a sequence allocation that was computer-generated and
used matching by key characteristics to place the clus-
tered clinics into match groups. Match criteria included
organization type and location; total patient population,
and the number of patients that were high risk according
to a standardized risk scoring system based on comorbidi-
ties that predict hospitalization. Sequence generation was
done by a random number seeded by time; matched pairs
of clinics are randomly allocated by this seed to either
intervention or control. For the patient experience of care
surveys, patients are randomly chosen by a computer pro-
gram, with oversampling of ‘high risk’ at 50% of the overallsample. The principal investigator (PI) wrote the
randomization algorithm, the matching criteria, and had
multiple team members approve them as fair, unbiased,
and without error prior to implementation. Once the pro-
gram was run, it was sent directly to the other team mem-
bers without intervention by the PI.
Blinding and consent
For blinding, incentives vary by arm and participants are
shown their own incentives. To partially blind them, the
terms ‘intervention’ and ‘control’ are not used, and all re-
ports are only shown to individual clinics without noting
differences between arms. Similarly, blinding for the
study team (to avoid experimenter’s bias) is not possible,
since the reports are seen across clinics by the team. To
reduce bias, the practice facilitator is required to log all
interactions and have these reviewed by a third party for
time equality (same resource amounts provided to each),
for minimal discussion of differences between clinics
and arms, and for similar internal milestone achieve-
ment by each clinic. Blinding for the analyst is planned,
with intervention and control arms labeled only as A
and B, and clinic and patient identifiers are masked.
Consent was sought from clinics, clinicians participating,
and patients receiving the CG-CAHPS survey; other data
collection is completed, done under a waiver of consent.
Statistical methods and analysis
Descriptive analysis will compare baseline characteristics
of clinics and individuals across outcomes and primary
confounders (demographics, chronic illnesses, previous
medical care, previous adherence to quality measures). A
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in rates of outcomes for intervention versus control. Pri-
mary analysis will be a multi-level, two-stage analysis to
account first for patient level and clinic level differences
and then changes over time. Modeling will be done using
generalized estimating equations; these can be adjusted for
the level and the outcome variable specifics. The risk of
selection bias by cluster is high, so to account for this, we
pre-assess the population by risk of hospitalization using a
standardized risk score prior to trial start. This group be-
comes the analytic cohort, and the size of each high-risk
group is used to stratify clusters. We will generate the
intracluster correlation, account for it by adjusting multi-
variate analysis, and perform propensity matching within
the analytic cohort to assure similarity of baseline cohorts
at the clinics. Overfitting will be tested using Copa’s test
and model fit using Hosmer-Lemeshow, receiver operating
curves, and Akaike information criterion for logistic-based
models and Box-Cox test, GLM family test, Link and RE-
SET test in addition to R2, and mean-squared error for
cost-based models.
Ethical approval and trial status
Ethical approval was granted by the Oregon Health and
Science University (OHSU) Institutional Review Board.
At the time of manuscript submission, the trial is on-
going. While primary data collection has concluded, we
are currently collecting data from CG-CAHPS surveys
and have not yet begun analysis on primary outcomes.
Discussion
The TOPMED trial is a cluster randomized controlled
trial to test whether focused quality improvement would
be superior to general quality improvement in achieving
cost and experience of care outcomes, especially for
high-risk patients, across eight clinics. The trial has a
pragmatic design, focusing on providing incentives, IT
support, and practice facilitation that are intended to
work in the real world of health reform and still allow
choice, autonomy, and flexibility for the clinical teams.
Several trial design aspects proved challenging and have
limitations. Sample size for number of clusters is low,
while the patient-to-cluster ratio is high. A report by
Mathematica on patient-centered medical home studies
completed a quantitative analysis that concluded 200
clinics (cluster level) with 10 patients each would have sig-
nificantly more power than 10 clinics with 200 patients
each [13]. However, stakeholders reflected to our study
team that the ability to understand what is happening in
each cluster can be extraordinarily complex—a clinic is an
organization made up of many different microsystems,
changing processes, and subpopulations of patients who
may self-select a particular microsystem based on their
needs; failing to measure these microsystems leads toerrors. In addition, significant resources are required to try
to alter processes within a single clinic, making studies
with large number of clusters expensive. Finally, measure-
ment of processes, structure, and other aspects of perform-
ance (e.g., culture) at the cluster level (in addition to the
patient level) is also resource consuming and yet may be
the single most important aspect of cluster RCTs—under-
standing processes and culture seems to dictate success in
many implementation science reviews. Blinding for a trial
design like this is not wholly possible. However, partial
blinding was used and independent review of facilitator per-
formance and scoring is intended to reduce this bias. For
analysis, multiple publications have discussed the frequent
need for post hoc adjustments in analyses, including
intracluster correlations, two-stage analysis, instrumental
variables, and propensity scoring as ways to adjust for base-
line differences in the individual patients. Although we use
two-stage analysis, differences in clusters or panels may still
persist and affect outcomes.
Conclusion
The Transforming Outcomes for Patients through Med-
ical home Evaluation and reDesign (TOPMED) trial was
designed as a pragmatic cluster randomized controlled trial
with community and stakeholder input. Final trial design is
a two-arm trial randomized at the clinic level with match-
ing to improve balance. Intervention and control arms
both receive equal incentives, IT support and integration,
and practice facilitation; Intervention is focused on a set of
literature- and stakeholder-identified high-value elements,
while control will be encouraged in general quality im-
provement activities. Outcomes will be the triple aim of
cost, patient experience of care, and population health.Additional file
Additional file 1: Proposed IT reports for intervention and
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